Browse the evidence

Patients older than 67 years showed a significant increase in fracture risk with GLP-1RA use, particularly those aged 68 to 77 years (5.61% vs. 3.65%, OR 2.25, CI [1.62 to 3.13]) and 78 to 88 years (9.28% vs. 5.10%, OR 4.99, CI [2.68 to 9.26]).

Older patients may be at higher risk for fractures when prescribed GLP-1RAs and should be monitored accordingly.

If access to GLP-1RAs was restricted to people with severe obesity and 50% moved into a lower BMI category, there would be a simulated reduction in cumulative cancer cases of 7476.

Restricting GLP-1RA access to those with severe obesity can still lead to significant cancer case reductions.

Patients receiving semaglutide within 10 days of surgery have a significantly increased risk of residual gastric content compared to a control sample (40% vs. 3%).

Clinicians should be cautious when managing patients on semaglutide in the peri-operative setting due to increased aspiration risk.

Increased residual gastric content was observed regardless of whether patients held semaglutide for 1–7 or 8–10 days pre-operatively.

The duration of holding semaglutide before surgery may not mitigate the risk of residual gastric content.

Increased residual gastric content can persist up to 10 days after stopping subcutaneous semaglutide.

Clinicians may need to consider longer pre-operative interruption intervals for patients on semaglutide to reduce aspiration risk.

Adverse side effects from GLP-1 receptor agonists are mostly gastrointestinal but may also include loss of muscle and bone mass.

Monitor for gastrointestinal side effects and potential muscle and bone mass loss in patients using GLP-1 receptor agonists.

The intervention subjects lost more weight than the control subjects (-4.1 kg vs -2.1 kg), but the difference was not statistically significant (p = 0.22).

Practitioners may consider remote dietitian support for weight loss in patients before joint surgery.

The intervention subjects had higher odds of achieving a BMI of <40 kg/m 2 (odds ratio = 1.9), but this was not statistically significant (p = 0.44).

Practitioners may find that remote interventions can help some patients achieve a healthier BMI before surgery.

Mitochondrial uncoupling promotes energy dissipation and may serve as a strategy for obesity treatment.

Practitioners may consider mitochondrial uncoupling as a potential target for obesity interventions.

Observational data show a reduction in all-cause mortality and cancer risk in patients who have undergone bariatric surgery.

Bariatric surgery may significantly improve long-term health outcomes and reduce mortality risk.

There has been limited success in curbing the incidence of T2D despite lifestyle modification being standard care.

Practitioners should recognize the barriers to effective lifestyle interventions.

PA may not be a critical factor influencing weight maintenance in PWD.

Weight maintenance strategies for PWD may need to consider factors beyond just physical activity.

There are trivial hypertrophic effects between proximal, mid-belly, and distal muscle sites.

Trivial differences in hypertrophy suggest that exercise selection may not need to prioritize specific muscle lengths.

GLP-1 receptor agonists may modify aortic disorders through anti-inflammatory, antioxidant, and antiatherogenic properties.

GLP-1 RAs could be considered for patients with aortic disorders due to their beneficial properties.

Metabolic drugs such as GLP-1-based therapies and SGLT2 inhibitors have benefits that extend beyond metabolic improvements into changes in chronic inflammation.

Practitioners should consider the anti-inflammatory potential of metabolic drugs in clinical settings.

Physical frailty and sarcopenia are associated with morbidity and 2-fold mortality in patients with advanced chronic liver disease awaiting liver transplantation.

Healthcare providers should assess frailty and sarcopenia in liver transplant candidates to improve outcomes.

Early identification of physical frailty in the liver transplantation clinical pathway is essential for targeted interventions.

Clinicians should implement screening tools for frailty in liver transplant candidates to tailor interventions.

Transient reductions in fasting glucose were observed in participants with T2D, but these were not sustained and not significantly different from placebo at day 29.

While LY3537021 may reduce fasting glucose, the effects may not be long-lasting.

The evidence supporting GLP-1RAs for treating PsO and PsA remains limited.

Further clinical research is needed to establish the efficacy and safety of GLP-1RAs for PsO and PsA.

Environmental cues such as chronic cold exposure, exercise, and caloric restriction potentiate adipocyte browning.

Incorporating cold exposure, exercise, and caloric restriction may enhance browning and its benefits.

Loss of muscle-related indices exceeded prespecified benchmarks in two thirds of incretin-based interventions.

Clinicians should monitor muscle mass when prescribing incretin therapies for weight loss.

High-dose canagliflozin (300 mg/day) is significantly associated with reduced sepsis risk versus control.

Practitioners may consider high-dose canagliflozin as a safer option regarding sepsis risk.

Treatment duration had minimal influence on primary outcomes.

Practitioners may not need to adjust treatment duration based on infection risk concerns.

All active treatments, including Dapagliflozin 10 mg, Survodutide, Tirzepatide, and higher-dose Semaglutide, improved fibrosis versus placebo.

Practitioners can consider these anti-diabetic agents as effective options for improving liver fibrosis in patients with MASH.